You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 53 No. 4, April 1996 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Single Photon Emission Computed Tomographic Blood Flow and Magnetic Resonance Volume Imaging of Basal Ganglia in Huntington's Disease

Gordon J. Harris, PhD; Elizabeth H. Aylward, PhD; Carol E. Peyser, MD; Godfrey D. Pearlson, MB,BS; Jason Brandt, PhD; Joy V. Roberts-Twillie, MD; Patrick E. Barta, MD, PhD; Susan E. Folstein, MD

Arch Neurol. 1996;53(4):316-324.


Abstract

Objective
To examine basal ganglia dysfunction and atrophy in patients with mild to moderate Huntington's disease, with correlation of imaging measures with clinical and neuropsychological measures.

Design
Survey study in patients with Huntington's disease and matched controls, with imaging measures being evaluated by investigators unaware of the diagnosis. Setting: Baltimore Huntington's Disease Project, The Johns Hopkins Hospital, Baltimore, Md.

Patients and Other Participants
Subjects included 10 patients with mild to moderate Huntington's disease and nine healthy age-matched control subjects. Main Outcome Measures: Imaging measures included single photon emission computed tomographic regional cerebral blood flow in caudate, putamen, and thalamus, and magnetic resonance imaging measures of caudate and putamen volumes and bicaudate ratios. Patients underwent neurologic and mental status examinations and neuropsychological tests. tween patients and control subjects was mean putamen volume, reduced 54.3% in patients, with no overlap between groups (P<.001). Of the cerebral blood flow measures, caudate showed the greatest difference (21.5% decrease; P<.001). Quantitative neurologic indexes of disease severity correlated with both putamen measures (P<.03), while Mini—Mental State Examination scores correlated with caudate volume (P<.02). Bicaudate ratio correlated with both clinical measures and was the best index of neurologic deterioration (r=.95; P<.001), while global atrophy (measured by cerebrospinal fluid percentage) was the best correlate of several neuropsychological tests, such as the Trail Making Test (r=.93; P<.001).

Results

The measure with the greatest difference be

Conclusions
Volumetric measurement of putamen best discriminated patients with Huntington's disease from healthy subjects. Measures of caudate atrophy or single photon emission computed tomographic measures performed less well. Neurologic decline correlated best with subcortical atrophy measured by the bicaudate ratio, but neuropsychological performance best corresponded to cerebrospinal fluid percentage, a measure of global atrophy.



Author Affiliations

From the Department of Psychiatry, Tufts University, New England Medical Center, Boston, Mass (Drs Harris and Folstein); Department of Psychiatry and Behavioral Sciences, The Johns Hopkins Medical Institutions, Baltimore, Md (Drs Aylward, Brandt, Roberts-Twillie, and Barta and Mr Pearlson); and Department of Psychiatry, Veterans Affairs Medical Center, Menlo Park, Calif (Dr Peyser).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Thalamic Atrophy in Huntington's Disease Co-varies with Cognitive Performance: A Morphometric MRI Analysis
Kassubek et al.
Cereb Cortex 2005;15:846-853.
ABSTRACT | FULL TEXT  

In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease
Fennema-Notestine et al.
Neurology 2004;63:989-995.
ABSTRACT | FULL TEXT  

Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy in Dementias
Hsu et al.
J Geriatr Psychiatry Neurol 2001;14:145-166.
ABSTRACT  

Subcortical volumes in girls with Tourette syndrome: Support for a gender effect
Zimmerman et al.
Neurology 2000;54:2224-2229.
ABSTRACT | FULL TEXT  

Decreased striatal monoaminergic terminals in Huntington disease
Bohnen et al.
Neurology 2000;54:1753-1759.
ABSTRACT | FULL TEXT  

Bradykinesia in early Huntington's disease
Sanchez-Pernaute et al.
Neurology 2000;54:119-119.
ABSTRACT | FULL TEXT  

Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease
Harris et al.
Brain 1999;122:1667-1678.
ABSTRACT | FULL TEXT  

Clinical correlation of striatal 1H MRS changes in Huntington's disease
Sanchez-Pernaute et al.
Neurology 1999;53:806-806.
ABSTRACT | FULL TEXT  

New Techniques for Understanding Huntington's Disease
Hurley et al.
J. Neuropsychiatry Clin. Neurosi. 1999;11:173-175.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.